ONOMA — demonstration

What a pharmaceutical brand-name review covers, shown on invented candidates.

Candidate shortlist (synthetic)

Candidate	What the review would examine	Assessment
Velmoryn	Stem separation against the register; nearest-neighbour look-alike and sound-alike checks.	Available after sign-in
Cardexa	Whether a crowded therapeutic prefix creates confusion with existing cardiovascular names.	Available after sign-in
Ostivera	Vowel rhythm and syllable structure; overlap with an established naming family.	Available after sign-in
Nuvexil	Whether a suffix implies a therapeutic class the product does not belong to.	Available after sign-in
Betrilume	Length and opening consonant; how the name survives handwriting and verbal orders.	Available after sign-in
Zaltrion	Initial-letter rarity and overall silhouette against the register.	Available after sign-in

Assessments are withheld here on purpose. This page shows what a review examines, never how any of it is weighed — no weights, no thresholds and no candidate results are published, and the page carries no script that could produce one.

What a review examines

Look-alike risk. Orthographic proximity to names already on the register.
Sound-alike risk. Phonetic proximity, including under verbal ordering.
Protected stems. Whether the name borrows a reserved INN or USAN stem.
Claim implication. Whether the name asserts efficacy or a class it should not.
Arabic reading and cultural fit. How the name transliterates and reads in market.
Nearest comparators. The closest existing names across the covered registers.

These are the dimensions a naming dossier addresses. Their relative weight, the bands applied to them and any resulting figure are part of the product and are not published.